Loading…
Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy
Aim Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation incre...
Saved in:
| Published in: | Diabetes, obesity & metabolism obesity & metabolism, 2013-03, Vol.15 (3), p.258-263 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23 |
| container_end_page | 263 |
| container_issue | 3 |
| container_start_page | 258 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 15 |
| creator | Meier, J. J. Pennartz, C. Schenker, N. Menge, B. A. Schmidt, W. E. Heise, T. Kapitza, C. Veldhuis, J. D. |
| description | Aim
Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion?
Methods
Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8‐week treatment period with insulin glargine. Glucose, insulin and C‐peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis.
Results
Insulin treatment lowered fasting glycaemia from 179.6 ± 7.5 mg/dl to 117.6 ± 6.5 mg/dl (p |
| doi_str_mv | 10.1111/dom.12022 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1282517842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1282517842</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23</originalsourceid><addsrcrecordid>eNp10MtO3DAUBmCralUu7aIvUFnqBhYBX-LEZocoDEi0bFpNd9YZ-wQMuWEnonl7MgzMolK9sS1959fRT8gXzo74fI591xxxwYR4R3Z5XsiMS1G8f3mLTBsmdsheSveMsVzq8iPZEZJJIwu2S24vpx7jbT05wCYADYlCSp0LMKCnT2G4o6HpIcT51491giHUSEObxjq0NKGLOISuPaFYVegG2lV0BQnqLRnuMEI_fSIfKqgTfn6998nvi_NfZ5fZ9c3i6uz0OnPScJEpUCC5dEZUWnuVV1oxAWrFVO69V6UxJjfMVYWXnnlTeqNWwhnJtOegUch9crDJ7WP3OGIabBOSw7qGFrsxWS60ULzU-Zp--4fed2Ns5-3WihutdJ7P6nCjXOxSiljZPoYG4mQ5s-v27dy-fWl_tl9fE8dVg34r3-qewfEGPM0tTv9Pst9vfrxFZpuJkAb8u52A-GCLUpbKLn8u7PKPXiyZktbIZypUnXc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1281985844</pqid></control><display><type>article</type><title>Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Meier, J. J. ; Pennartz, C. ; Schenker, N. ; Menge, B. A. ; Schmidt, W. E. ; Heise, T. ; Kapitza, C. ; Veldhuis, J. D.</creator><creatorcontrib>Meier, J. J. ; Pennartz, C. ; Schenker, N. ; Menge, B. A. ; Schmidt, W. E. ; Heise, T. ; Kapitza, C. ; Veldhuis, J. D.</creatorcontrib><description>Aim
Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion?
Methods
Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8‐week treatment period with insulin glargine. Glucose, insulin and C‐peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis.
Results
Insulin treatment lowered fasting glycaemia from 179.6 ± 7.5 mg/dl to 117.6 ± 6.5 mg/dl (p < 0.001). Postprandial insulin and C‐peptide levels increased significantly after the treatment period (p < 0.0001). The total calculated insulin secretion rate increased with insulin treatment (p = 0.0039), with non‐significant increases in both pulsatile and non‐pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2 = 0.51 and 0.56, respectively), whereas non‐pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2 = 0.0073 and 0.031).
Conclusions
Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β‐cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.12022</identifier><identifier>PMID: 23039360</identifier><identifier>CODEN: DOMEF6</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Blood Glucose - drug effects ; Blood Glucose - metabolism ; C-Peptide - metabolism ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes Mellitus, Type 2 - physiopathology ; Female ; Humans ; Hyperglycemia - blood ; Hyperglycemia - drug therapy ; Hyperglycemia - metabolism ; Hyperglycemia - physiopathology ; Insulin - blood ; Insulin - metabolism ; Insulin Glargine ; Insulin Secretion ; insulin therapy ; Insulin, Long-Acting - metabolism ; Male ; Middle Aged ; Postprandial Period ; Treatment Outcome ; β-cell</subject><ispartof>Diabetes, obesity & metabolism, 2013-03, Vol.15 (3), p.258-263</ispartof><rights>2012 Blackwell Publishing Ltd</rights><rights>2012 Blackwell Publishing Ltd.</rights><rights>2013 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23</citedby><cites>FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23039360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meier, J. J.</creatorcontrib><creatorcontrib>Pennartz, C.</creatorcontrib><creatorcontrib>Schenker, N.</creatorcontrib><creatorcontrib>Menge, B. A.</creatorcontrib><creatorcontrib>Schmidt, W. E.</creatorcontrib><creatorcontrib>Heise, T.</creatorcontrib><creatorcontrib>Kapitza, C.</creatorcontrib><creatorcontrib>Veldhuis, J. D.</creatorcontrib><title>Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aim
Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion?
Methods
Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8‐week treatment period with insulin glargine. Glucose, insulin and C‐peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis.
Results
Insulin treatment lowered fasting glycaemia from 179.6 ± 7.5 mg/dl to 117.6 ± 6.5 mg/dl (p < 0.001). Postprandial insulin and C‐peptide levels increased significantly after the treatment period (p < 0.0001). The total calculated insulin secretion rate increased with insulin treatment (p = 0.0039), with non‐significant increases in both pulsatile and non‐pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2 = 0.51 and 0.56, respectively), whereas non‐pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2 = 0.0073 and 0.031).
Conclusions
Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β‐cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.</description><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>C-Peptide - metabolism</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperglycemia - blood</subject><subject>Hyperglycemia - drug therapy</subject><subject>Hyperglycemia - metabolism</subject><subject>Hyperglycemia - physiopathology</subject><subject>Insulin - blood</subject><subject>Insulin - metabolism</subject><subject>Insulin Glargine</subject><subject>Insulin Secretion</subject><subject>insulin therapy</subject><subject>Insulin, Long-Acting - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Postprandial Period</subject><subject>Treatment Outcome</subject><subject>β-cell</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp10MtO3DAUBmCralUu7aIvUFnqBhYBX-LEZocoDEi0bFpNd9YZ-wQMuWEnonl7MgzMolK9sS1959fRT8gXzo74fI591xxxwYR4R3Z5XsiMS1G8f3mLTBsmdsheSveMsVzq8iPZEZJJIwu2S24vpx7jbT05wCYADYlCSp0LMKCnT2G4o6HpIcT51491giHUSEObxjq0NKGLOISuPaFYVegG2lV0BQnqLRnuMEI_fSIfKqgTfn6998nvi_NfZ5fZ9c3i6uz0OnPScJEpUCC5dEZUWnuVV1oxAWrFVO69V6UxJjfMVYWXnnlTeqNWwhnJtOegUch9crDJ7WP3OGIabBOSw7qGFrsxWS60ULzU-Zp--4fed2Ns5-3WihutdJ7P6nCjXOxSiljZPoYG4mQ5s-v27dy-fWl_tl9fE8dVg34r3-qewfEGPM0tTv9Pst9vfrxFZpuJkAb8u52A-GCLUpbKLn8u7PKPXiyZktbIZypUnXc</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>Meier, J. J.</creator><creator>Pennartz, C.</creator><creator>Schenker, N.</creator><creator>Menge, B. A.</creator><creator>Schmidt, W. E.</creator><creator>Heise, T.</creator><creator>Kapitza, C.</creator><creator>Veldhuis, J. D.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy</title><author>Meier, J. J. ; Pennartz, C. ; Schenker, N. ; Menge, B. A. ; Schmidt, W. E. ; Heise, T. ; Kapitza, C. ; Veldhuis, J. D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>C-Peptide - metabolism</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperglycemia - blood</topic><topic>Hyperglycemia - drug therapy</topic><topic>Hyperglycemia - metabolism</topic><topic>Hyperglycemia - physiopathology</topic><topic>Insulin - blood</topic><topic>Insulin - metabolism</topic><topic>Insulin Glargine</topic><topic>Insulin Secretion</topic><topic>insulin therapy</topic><topic>Insulin, Long-Acting - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Postprandial Period</topic><topic>Treatment Outcome</topic><topic>β-cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meier, J. J.</creatorcontrib><creatorcontrib>Pennartz, C.</creatorcontrib><creatorcontrib>Schenker, N.</creatorcontrib><creatorcontrib>Menge, B. A.</creatorcontrib><creatorcontrib>Schmidt, W. E.</creatorcontrib><creatorcontrib>Heise, T.</creatorcontrib><creatorcontrib>Kapitza, C.</creatorcontrib><creatorcontrib>Veldhuis, J. D.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meier, J. J.</au><au>Pennartz, C.</au><au>Schenker, N.</au><au>Menge, B. A.</au><au>Schmidt, W. E.</au><au>Heise, T.</au><au>Kapitza, C.</au><au>Veldhuis, J. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2013-03</date><risdate>2013</risdate><volume>15</volume><issue>3</issue><spage>258</spage><epage>263</epage><pages>258-263</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><coden>DOMEF6</coden><abstract>Aim
Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion?
Methods
Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8‐week treatment period with insulin glargine. Glucose, insulin and C‐peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis.
Results
Insulin treatment lowered fasting glycaemia from 179.6 ± 7.5 mg/dl to 117.6 ± 6.5 mg/dl (p < 0.001). Postprandial insulin and C‐peptide levels increased significantly after the treatment period (p < 0.0001). The total calculated insulin secretion rate increased with insulin treatment (p = 0.0039), with non‐significant increases in both pulsatile and non‐pulsatile insulin secretion. Insulin pulse frequency was unchanged by the intervention. There was an inverse relationship between fasting and postprandial glycaemia and insulin pulse mass (r2 = 0.51 and 0.56, respectively), whereas non‐pulsatile insulin secretion was unrelated to either fasting or postprandial glucose concentrations (r2 = 0.0073 and 0.031).
Conclusions
Hyperglycaemia in type 2 diabetes is associated with a reduction in postprandial insulin secretion, specifically through a reduction in insulin pulsatility. Reducing chronic hyperglycaemia by basal insulin therapy enhances endogenous β‐cell function in the postprandial state. These data support the use of basal insulin regimens in the pharmacotherapy of overtly hyperglycaemic patients with type 2 diabetes.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>23039360</pmid><doi>10.1111/dom.12022</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2013-03, Vol.15 (3), p.258-263 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1282517842 |
| source | Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list) |
| subjects | Blood Glucose - drug effects Blood Glucose - metabolism C-Peptide - metabolism Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Female Humans Hyperglycemia - blood Hyperglycemia - drug therapy Hyperglycemia - metabolism Hyperglycemia - physiopathology Insulin - blood Insulin - metabolism Insulin Glargine Insulin Secretion insulin therapy Insulin, Long-Acting - metabolism Male Middle Aged Postprandial Period Treatment Outcome β-cell |
| title | Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T00%3A12%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperglycaemia%20is%20associated%20with%20impaired%20pulsatile%20insulin%20secretion:%20effect%20of%20basal%20insulin%20therapy&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Meier,%20J.%20J.&rft.date=2013-03&rft.volume=15&rft.issue=3&rft.spage=258&rft.epage=263&rft.pages=258-263&rft.issn=1462-8902&rft.eissn=1463-1326&rft.coden=DOMEF6&rft_id=info:doi/10.1111/dom.12022&rft_dat=%3Cproquest_cross%3E1282517842%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3912-5a5a313c92f88d54f8502a5b054ddd57999490cf6d3d0d97d95b2c9308d1a8e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1281985844&rft_id=info:pmid/23039360&rfr_iscdi=true |